Comparison of Patients with Ultrasound Guided Tru-Cut Biopsy / Acid Cytology with Final Pathology Results from Patients Operated with Suspicious for Ovarian Cancer

Abstract

Objective In women who are believed to have ovarian cancer but have poor performance status or have advanced disease believed to be beyond the scope of primary cytoreductive surgery, NACT can be given to patients with acid cytology and/or tru-cut biopsy referral. Our aim is to determine the accuracy, adequacy, safety and reliability of these minimally invasive interventional procedures. Material and Methods This is a retrospective analysis of 63 patients with a suspicioused of ovarian cancer in our hospital between 2014 and 2021, who underwent ultrasound-guided acid cytology and tru-cut biopsy, and also had postoperative final pathology results. Results Comparing acid cytology, tru-cut biopsy, acid cytology and tru-cut biopsy at the same time with the postoperative final pathology results, it was seen that the PPV was 100% in all groups. It was revealed that the sensitivity of acid cytology was 64%, the specificity was 100%, the NPV was 12%, and the accuracy of the test was 65%. The sensitivity of the tru-cut biopsy was 91%, the specificity was 100%, the NPV was 42%, and the accuracy of the test was 92%. In the case of both procedures, the sensitivity was calculated as 93% and the accuracy of the test was calculated as 93%. There were no false positive cytology and biopsy results that could lead to unnecessary NACT therapy in the study. Conclusion Minimally invasive procedures can be safely applied to patients with low adverse event and high accuracy rates, since they provide NACT in patients who are thought to be candidates for interval surgery.